EDEN PRAIRIE, Minn., July 1, 2018 /PRNewswire/ -- MIVI Neuroscience, Inc. announced today the expansion of its European commercializationnetwork with the commitment from AngioNautix of Madrid, Spain, to be its partner in Spain, Portugal and Cuba. CE Mark approval for the R4Q Revascularization
AngioNautix joins Neurologic Europe Ltd. in the United Kingdom, and Med-Italia Biomedica, S.r.l. in Italy as MIVI's partners. Each organizations is a fully integrated industry leader in the neurovascular space with significant experience in launching novel, patient focused technologies.
"We are very excited to add AngioNautix to the team at MIVI," said Jim McCollum, MIVI's CEO. "We believe our partners will be effective in delivering our complete suite of products - including our family of Mi-Axus Guide Catheters and now the R4Q Revascularization System - to their unique interventional neurovascular communities."
About MIVI Neuroscience
MIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures. Adoption of endovascular stroke therapy procedures is growing significantly worldwide since compelling data from multiple large-scale randomized trials in 2016 and 2017 confirmed the value to rapidly clear occlusive clot from large cerebral vessels. MIVI's innovative product portfolio provides physicians with unique devices designed to improve patient outcomes in these procedures by reducing complications, shortening procedure times and expanding treatment to more patients. More information about MIVI can be found on the website, www.mivineuro.com.
View original content:http://www.prnewswire.com/news-releases/mivi-neuroscience-expands-european-commercialization-network-after-achieving-ce-mark-approval-of-the-r4q-revascularization-catheter-for-ischemic-stroke-300675098.html
SOURCE MIVI Neuroscience
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All